James Frew

James Frew bought 25,000 AMPY shares at $3.95 on 2026-06-23; stock down -42.1% from 52-week high, posting losses in 2 of 3 recent same-ticker buys.

James Frew purchased 25,000 shares at $3.95, increasing his holdings from 191.9K to 216.9K shares (+13.0%). The stock is trading at $3.93, down -42.1% from the 52-week high of $6.79 and -21.6% over the past 30 days. At the same ticker, Frew's recent trading history is mixed: two 2025 August buys achieved strong 90-day returns (+7.6% and +13.4%), but his March 2025 and November 2023 purchases both produced negative 90-day outcomes (-24.4% and -2.3%, respectively). The company is reporting a net loss of $-38.1M against revenue of $37.5M, with annual revenue declining -10.6% year-over-year, indicating financial stress that may explain the depressed valuation. Frew's buy history at this ticker shows inconsistent timing success, and the current purchase occurs when fundamentals are materially weak.

Insider purchases 75,000 AMPY shares in 2 transactions for $267,500, raising holdings +138.3%; prior AMPY buys returned -24.4% and -2.3% over 90 days.

James Frew made two separate open-market purchases totaling 75,000 shares for $267,500.00 at a blended average price of $3.57, increasing his holdings from 54,222 to 129,222 shares (+138.3%). The current price of $3.87 is -48.5% from the 52-week high of $7.51, and the stock has appreciated +15.2% over the past 30 days and +33.0% over 90 days. However, his track record at this ticker is unfavorable: his 2 prior purchases at AMPY resulted in 90-day returns of -24.4% (from March 2025) and -2.3% (from November 2023), with a 0% win rate at the 90-day mark. His cross-ticker track record shows 2 prior buys with an average 90-day return of -9.4%, also with a 0% win rate, suggesting a consistent pattern of unfavorable timing on purchases across holdings.

AMPY insider FREW JAMES buys 15,000 shares at $3.85; stock down 50.2% from 52-week high amid cluster activity.

FREW JAMES purchased 15,000 shares at $3.85 on 2025-03-07, increasing holdings by 38.2% from 39,222 to 54,222 shares. The transaction occurs in a context of material deterioration: the stock has fallen -50.2% from its 52-week high and -23.8% over the past 30 days. Notably, 2 other insiders also bought within the past 14 days, suggesting coordinated accumulation at depressed levels. However, the insider's cross-ticker track record shows a 0% 90-day win rate with average 90-day returns of -3.1%, and his sole prior trade at AMPY (buy on 2023-11-08) likewise posted negative 90-day performance. The company itself shows modest fundamentals (P/E 12.77, $22.7M net income) but contracting revenue (-4.2% year-over-year), which combined with the insider's poor prior timing history, provides limited conviction signal for this accumulation.